ArticleMicrobial biotechnology2026
From Mycosynthesis to Immunomodulation: Exploring the Safety, Adjuvant Potential and Microbiota Impact of Biogenic Silver Nanoparticles.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Subunit vaccines are considered the safest immunization platforms but typically require adjuvants to elicit robust immune responses. Although nanoparticles have emerged as promising adjuvants, biogenic silver nanoparticles (AgNPs) produced by mycosynthesis remain largely unexplored. Herein, nine different AgNPs were mycosynthesized using local strains of Phanerochaete chrysosporium, Penicillium expansum and Punctularia atropurpurascens grown in three different culture media (PDB, MEB, MGYP). Mycosynthesized AgNPs were all shown to be spherical, negatively charged and containing fungal proteins within the biomolecular capping. Additionally, although in vitro biocompatibility assessments showed AgNPs-specific differences in haemolytic and cytotoxic activities, no signs of acute toxicity were observed in mice. The adjuvant potential of AgNPs was further evaluated in ovalbumin-immunized mice, showing that four AgNPs displayed significant immunoenhancement activity with an outstanding IgG
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.